Advertisement

Cor homini lupus? Identification of risk factors implicated in cardiovascular events in patients with Systemic Lupus Erythematosus in Romania

Published:February 17, 2021DOI:https://doi.org/10.1016/j.ejim.2021.02.007
      Cardiovascular disease (CVD) accounts for up to 35% of mortality in patients with systemic lupus erythematosus (SLE) [

      Deane K. Cardiovascular Disease a Leading Cause of Death in Lupus. Medscape.

      ]. Emerging evidence supports that SLE disease activity is associated with up to two times higher cardiovascular (CV) risk than traditional risk factors [
      • Pucci G
      • Vaudo G.
      Cardiac and vascular damage in systemic erythematosus lupus. Is disease activity the mediator?.
      ]. According to an interesting recent study of Salvetti et al. left ventricular function in premenopausal women suffering from SLE was inferior compared to control subjects matched for sex, age, body mass index (BMI), blood pressure and antihypertensive therapy. Moreover, the femoral and carotid pulse wave velocity were affected by the treatment of SLE with steroids [
      • Salvetti M
      • Paini A
      • Andreoli L
      • et al.
      Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences?.
      ]. These findings suggest that younger SLE patients are not spared from cardiovascular disease [

      Deane K. Cardiovascular Disease a Leading Cause of Death in Lupus. Medscape.

      ]. Hence, identifying further risk factors associated with CV events in SLE is essential, in order to improve CV care and decrease CV morbidity and mortality among these patients.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Deane K. Cardiovascular Disease a Leading Cause of Death in Lupus. Medscape.

        • Pucci G
        • Vaudo G.
        Cardiac and vascular damage in systemic erythematosus lupus. Is disease activity the mediator?.
        Eur J Intern Med. 2020; 73: 23-24https://doi.org/10.1016/j.ejim.2020.01.013
        • Salvetti M
        • Paini A
        • Andreoli L
        • et al.
        Cardiovascular target organ damage in premenopausal systemic lupus erythematosus patients and in controls: Are there any differences?.
        Eur J Intern Med. 2020; 73: 76-82https://doi.org/10.1016/j.ejim.2019.12.001
        • Ward MM
        • Pyun E
        • Studenski S.
        Causes of death in systemic lupus erythematosus. Long-term followup of an inception cohort.
        Arthritis Rheum. 1995; 38: 1492-1499https://doi.org/10.1002/art.1780381016
        • Petri MA
        • Barr E
        • Magder LS.
        Development of a systemic lupus erythematosus cardiovascular risk equation.
        Lupus Sci & Med. 2019; 6e000346https://doi.org/10.1136/lupus-2019-000346
        • Monção CSA
        • Martins LN
        • Penteado MPS
        • et al.
        Incidence of cardiovascular risk factors in female patients with systemic lupus erythematosus: a 3-year follow-up cohort.
        Lupus. 2018; 27: 1790-1798https://doi.org/10.1177/0961203318790676
        • Toloza SMA
        • Uribe AG
        • McGwin GJ
        • et al.
        Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events.
        Arthritis Rheum. 2004; 50: 3947-3957https://doi.org/10.1002/art.20622
        • Wang X-Y
        • Tang X-Q
        • Huang Y-J
        • Chen W-Y
        • Yu X-Q.
        Frequency of established cardiovascular disease and its risk factors in Chinese patients with systemic lupus erythematosus.
        Clin Rheumatol. 2012; 31: 669-675https://doi.org/10.1007/s10067-011-1910-3
        • Di Minno MND
        • Forte F
        • Tufano A
        • et al.
        Speckle tracking echocardiography in patients with systemic lupus erythematosus: A meta-analysis.
        Eur J Intern Med. 2020; 73: 16-22https://doi.org/10.1016/j.ejim.2019.12.033
        • Mosca M
        • Boumpas DT
        • Bruce IN
        • et al.
        Treat-to-target in systemic lupus erythematosus: where are we today?.
        Clin Exp Rheumatol. 2012; 30: 112-115